Stay updated on T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.
    Difference
    0.3%
    Check dated 2024-10-03T04:49:49.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to version v2.11.0, while a notice regarding delays in displaying study record information has been removed.
    Difference
    4%
    Check dated 2024-09-25T22:24:40.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    ClinicalTrials.gov is addressing delays in displaying study record information, and the site has been updated to version 2.10.5, replacing the previous version 2.10.3.
    Difference
    4%
    Check dated 2024-09-18T16:31:47.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.2 to 2.10.3.
    Difference
    0.3%
    Check dated 2024-09-04T04:15:09.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    New content was added on August 27, 2024, following the removal of previous content on July 11, 2024.
    Difference
    0.7%
    Check dated 2024-08-28T02:11:31.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.
    Difference
    0.3%
    Check dated 2024-08-13T22:43:38.000Z thumbnail image

Stay in the know with updates to T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.